InspireMD (NYSE:NSPR) Director Gary Roubin Acquires 90,000 Shares

InspireMD, Inc. (NYSE:NSPR) Director Gary Roubin purchased 90,000 shares of InspireMD stock in a transaction that occurred on Thursday, May 7th. The shares were purchased at an average price of $1.18 per share, for a total transaction of $106,200.00. Following the transaction, the director directly owned 834,478 shares in the company, valued at $984,684.04. This represents a 12.09% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $1.15 on Friday. InspireMD, Inc. has a 1 year low of $1.02 and a 1 year high of $2.93. The stock has a market capitalization of $53.93 million, a price-to-earnings ratio of -1.53 and a beta of 0.82. The company’s 50 day simple moving average is $1.51 and its 200 day simple moving average is $1.75.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NSPR. Lake Street Capital set a $4.00 price target on InspireMD in a report on Monday. Maxim Group began coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday. Finally, Loop Capital set a $5.00 target price on InspireMD in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $4.50.

Institutional Trading of InspireMD

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of InspireMD in the 4th quarter valued at $30,000. Virtu Financial LLC acquired a new stake in shares of InspireMD during the 4th quarter valued at $31,000. Creative Planning bought a new stake in InspireMD during the 2nd quarter worth $44,000. Uniting Wealth Partners LLC bought a new stake in InspireMD during the 3rd quarter worth $51,000. Finally, Legato Capital Management LLC acquired a new position in InspireMD in the 4th quarter worth about $48,000. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.